Refine by
Innate Immunity Articles & Analysis
59 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
With a strong focus on unpicking the glycobiology of the innate immune system, the group seeks to advance molecular and cellular understanding of the role of glycoproteins in immune-related disorders including in cancer and inflammation and upon pathogen infections including sepsis, tuberculosis and cystic fibrosis. ...
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted in a statistically ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immune activator for the treatment of aggressive forms of prostate cancer. ...
Highlights: ES004 recognizes pan-allele human SIRPα with high affinity ES004 binds to a unique epitope on the CD47 binding domain of SIRPα ES004 potently blocks CD47-SIRPα interaction and CD47 induced SIRPα signaling ES004 effectively potentiates pan-allelic macrophage phagocytosis of tumor cells ES004 has no negative impact on T cell activation ES004 enhances ...
.: 793 Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST) 4. Title: Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity Abstract No.: 1211 Date and time: 11/10/2022, 9:00 am - 9:00 pm (EST) 5. ...
IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. ...
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
“Chris brings a wealth of industry experience to Immune-Onc at an exciting stage in the company’s evolution,” said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. ...
The trial sponsor is INmune Bio, a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that harness the patient’s innate immune system to fight disease. The trial will use CDM® technology to assess the efficacy of XPro™ compared with placebo on grey matter integrity in patients with mild AD. ...
Immune-Onc retains global development and commercial rights to IO-108 and IO-202. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. ...
The combination of IO-108 and anti-PD-1 may enable more patients across multiple solid tumor types to benefit from immune checkpoint inhibitors,” commented by Maggie Gu, China general manager of Immune-Onc. ...
” PreHevbri was approved by the European Commission (EC) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter of 2022 for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. ...
Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint ...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant ...
Gamma-delta T cells are the prototype of ‘unconventional’ T cells, having both innate and adaptive immune properties. These unique properties hold promise in treating solid tumors, the ‘Achilles heel’ of adoptive cell therapies. ...
Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio. PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. ...